Cegedim has announced the launch of its Health Data Business in support of pharmaceutical companies, clinical research organizations, and academic institutions.
Healthcare technology and services company, Cegedim, has announced the launch of its Health Data Business in support of pharmaceutical companies, clinical research organizations, and academic institutions, in a July 1, 2019 press release.
Customers of Cegedim’s data business will be offered access to more than 56 million anonymized real-world patient records, which are available through The Health Improvement Network (THIN) database. Through these data, it is hoped that companies will be able to drive improvements in patient care and outcomes.
Additionally, Cegedim announced the launch of a cloud-based solution, Health Data Lab, which provides business intelligence and analytics. The data lab uses THIN data alongside predefined calculations around aggregated data to gain an understanding of market trends, or can be used for more specific questions, such as treatment pathways, with bespoke analysis.
“Our THIN database has been a trusted data source, powering advancements in the healthcare industry, for some time. It is one of the most respected and reliable data sources for anonymized patient data,” said Steve Bradley, group managing director, Cegedim UK, in the press release. “We now want to help our customers to think outside the box and further improve patient outcomes by using our expertise and analytical solutions to better understand the wider healthcare economy. Cegedim Health Data and the Health Data Lab have been born from the belief that high data quality, management, and insights are the key to a better way of addressing current patient pathways, trends, and making significant improvements across the healthcare sector.”
Source: Cegedim
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.